MENU
Showcases Stock ranks Forex

Nkarta Inc (NKTX)
16.19  1.3 (8.73%) 08-08 16:00
Open: 15 Pre. Close: 14.89
High: 16.22 Low: 14.95
Volume: 1,119,582 Market Cap: 784M
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 16.23 - 16.278 16.278 - 16.331
Low: 14.812 - 14.867 14.867 - 14.93
Close: 16.085 - 16.175 16.175 - 16.275
Stock Technical Analysis
Overall:     
Target: Six months: 18.94
One year: 22.13
Support: Support1: 13.77
Support2: 12.25
Resistance: Resistance1: 16.22
Resistance2: 18.94
Pivot: 13.71
Moving Averages: MA(5): 14.21
MA(20): 13.76
MA(100): 13.16
MA(250): 15.90
MACD: MACD(12,26): 0.27
Signal(12,26,9): 0.05
%K %D: %K(14,3): 75.71
%D(3): 54.81
RSI: RSI(14): 67.35
52-Week: High: 39.583
Low: 7.55
Change(%): -54.7
Average Vol(K): 3-Month: 702
10-Days: 537
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ NKTX ] has closed Bollinger Bands are 35.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Tue, 09 Aug 2022
Affymax (OTCMKTS:AFFY) & Nkarta (NASDAQ:NKTX) Financial Comparison - Defense World

Sun, 07 Aug 2022
Over 100% Upside: Analysts See an Appealing Entry Point in These 3 'Strong Buy' Stocks - TipRanks

Tue, 26 Jul 2022
Nkarta, Inc. (NASDAQ:NKTX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Mon, 25 Jul 2022
Nkarta Announces Key Senior Leadership Team Appointments - GlobeNewswire

Tue, 19 Jul 2022
Nkarta (NASDAQ:NKTX) Now Covered by Analysts at SVB Leerink - Defense World

Mon, 18 Jul 2022
SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside - Benzinga

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 32.95
Shares Float (M) 32.20
% Held by Insiders 7.30
% Held by Institutions 67.39
Shares Short (K) 6280
Shares Short Prior Month (K) 5480
Stock Financials
EPS -2.470
Book Value (p.s.) 8.200
Profit Margin
Operating Margin
Return on Assets (ttm) -18.4
Return on Equity (ttm) -34.7
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -2.761
Qtrly Earnings Growth
Operating Cash Flow (M) -71.54
Levered Free Cash Flow (M) -48.79
Stock Valuation
PE Ratio -6.55
PEG Ratio
Price to Book value 1.97
Price to Sales
Price to Cash Flow -7.46
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android